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BACKGROUND: Treatment of bronchiectasis includes drugs, oxygen therapy, and bronchial-
clearance maneuvers. OBJECTIVE: To assess the safety and efficacy of intrapulmonary percussive
ventilation (IPV) compared to traditional standard chest physical therapy in patients with bron-
chiectasis and productive cough. METHODS: In a randomized crossover study, 22 patients under-
went, on consecutive days, IPV and chest physical therapy. Before each treatment session, imme-
diately after the session, 30 min after the session, and 4 hours after the session we measured SpO2,
heart rate, respiratory rate, and (with a visual analog scale) the patient’s subjective sensation of
phlegm encumbrance and dyspnea. Immediately after each treatment session we also measured (via
visual analog scale) the patient’s discomfort. We also measured the volume and wet and dry weight
of collected sputum. RESULTS: No adverse effects were so severe as to require discontinuation of
treatment, and the incidence of adverse effects was similar in the groups (27%). Heart rate (P .002)
and respiratory rate (P  .047) decreased during treatment, and sensation of phlegm encumbrance
improved (P  .03) with both treatments. Only IPV improved (P  .004) the sensation of dyspnea.
The patients found IPV more comfortable than our traditional standard chest physical therapy
(P  .03). Both treatments caused important phlegm production, but there were no differences in
sputum volume, wet weight, or dry weight. CONCLUSIONS: In patients with bronchiectasis and
productive cough, short-term IPV was as safe and effective as traditional chest physical therapy,
with less discomfort. Key words: bronchiectasis; intrapulmonary percussive ventilation; chest physical
therapy; rehabilitation; hypersecretion; airway and pulmonary infections. [Respir Care 2011;56(7):984–
988. © 2011 Daedalus Enterprises]
Introduction
Proper functioning of bronchial clearance relies on bal-
ance between mucus production, transport, and clearance.1
Impairment of this balance can result in phlegm encum-
brance, together with changes in physiological clearance
mechanisms.1 This can favor recurrent infections, affect
ventilatory function, and create a vicious circle of infec-
tions and inflammation that can ultimately lead to airway
and lung parenchyma destruction.1
Bronchiectasis, a disease that is being diagnosed with
increasing frequency,2 consists of segmental dilatation of
medium-size bronchi, due to loss of the muscle and elastic
components of the bronchial wall in patients without cys-
tic fibrosis (CF). Bronchiectasis is usually associated with
chronic cough, increasing secretions, and recurrent airway
and pulmonary infections that might result in loss of lung
function and lead to early death.2 The goals of bronchiec-
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tasis treatment are to reduce the number of exacerbations
and infections and to improve patient quality of life by
reducing airway inflammation and mobilizing secretions.3,4
Depending on the degree of lung function impairment,
accepted standard treatment includes drugs, oxygen ther-
apy, and daily bronchial-clearance maneuvers.3 Proposed
secretion management techniques include standard5 and
modified1,5 postural drainage, assisted cough,5 active cycle
of breathing techniques,5,6 autogenic drainage,5 inspiratory
muscle endurance training,6 oscillatory positive-expirato-
ry-pressure devices (eg, Flutter5 and Acapella6), and in-
trapulmonary percussive ventilation (IPV). Although the
treatment of mucus hypersecretion is recommended in
chronic respiratory diseases,1 there have been no definitive
studies or guidelines on preference of one clearance tech-
nique versus the others.7
IPV is powered with a pressure of about 50 cm H2O and
delivers small bursts of high-flow gas at 100–300 cycles/
min,8 which causes airway pressure changes of
5–35 cm H2O, and vibrates the airway walls. IPV im-
proves airway secretion clearance in CF patients,9,10 Duch-
enne muscular dystrophy,11 pediatric patients with atelec-
tasis,12 COPD exacerbation,13,14 obesity,15 tracheostomized
patients16 and patients with acute respiratory failure.13 To
our knowledge there have been no trials of IPV in patients
with bronchiectasis. We compared the safety, comfort, and
efficacy of IPV and our standard traditional chest physical
therapy (CPT) method in airway secretion clearance in
adult patients with bronchiectasis.
Methods
This study was approved by the ethic committees of
both Fondazione Maugeri Istituto di Ricovero e Cura a
Carattere Scientifico, Lumezzane, Italy, and Ospedale
Privato Accreditato Villa Pineta, Gaiato, Italy. All patients
gave written informed consent.
Patients
We screened all consecutive patients admitted to the
respiratory departments of our 2 institutions, from Sep-
tember 2005 to March 2008. The inclusion criteria were:
• Diagnosis of bronchiectasis based on computed tomo-
gram
• Daily sputum volume  20 mL for at least 2 consecu-
tive days
• Clinical stability: no need for medication changes 4 days
prior to enrollment
• Normal gas exchange: pH  7.35 during spontaneous
breathing, with or without supplemental oxygen
• No use of sedatives or vasopressors
• No major cardiac arrhythmias or hemodynamic instabil-
ity (eg, severe hypotension, sepsis, or low cardiac out-
put)
The exclusion criteria were tracheostomy, long-term non-
invasive ventilation (NIV), severe and/or irreversible sen-
sory abnormalities, and chest radiograph changes.
The drop-out criteria were withdrawal of patient con-
sent, severe clinical worsening, and occurrence of any of
the exclusion criteria.
Protocol
We used a randomized crossover design. On 2 consec-
utive days, each patient performed one of the secretion
clearance techniques on the first day and the other tech-
nique on the second day, per a computerized randomiza-
tion list. Both secretion clearance sessions were 30 min-
utes long. If the patient was on supplemental oxygen, the
oxygen flow was maintained constant during both treat-
ments.
Intrapulmonary Percussive Ventilation
IPV was provided with the IMP2 (Breas Medical, Mo¨ln-
lycke, Sweden). Each IPV session included 3 active cy-
cles, including 2 phases at low pressure and high fre-
quency, and another phase at high pressure and low
frequency. The patient was in a sitting position. At the end
of each cycle the respiratory therapist required the patient
to cough. The session was performed without delivery
aerosol therapy.
Chest Physical Therapy
CPT consisted of a combination of forced expiration,
postural drainage, percussion, and vibration.17,18 Each of 3
positions (prone, right-lateral decubitus, and left-lateral de-
cubitus) was maintained for 10 min, and after each posi-
tion the patient sat upright for 3 min of coughing.
Measurements
At baseline we recorded demographics, anthropometry,
respiratory function, PaO2, PaCO2, and pH. Before each treat-
ment session (time zero [T0]), immediately after the ses-
sion (T1), 30 min after the session (T2), and 4 hours after
the session (T3) we measured SpO2, heart rate, respiratory
rate, and (with a visual analog scale19) the patient’s sub-
jective sensation of phlegm encumbrance and dyspnea. At
T1 we also measured the patient’s subjective discomfort
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with a 0–100% discomfort visual analog scale.20 We also
measured the volume and wet and dry weight of collected
sputum. We asked the patients about adverse effects
throughout the 30-min treatment session and at T3.
Statistical Analysis
Statistical assumption for paired t test power calculation
was made on the efficacy. On the grounds of our previous
experience we estimated an 80% power to detect a reduc-
tion of 6 points in the average value of the efficacy pro-
portion between the 2 treatments. Differences were con-
sidered significant when P  .05. The estimated number
of patients to be enrolled was 22. Data analysis was with
statistics software (SPSS 12.0, SPSS, Chicago, Illinois).
Though we randomized the order of treatments, we could
not rule out the possibility that the order of treatment or a
learning effect might affect our results, so we divided the
patients into 2 groups according to random order: IPV
first, and CPT first. We tested for a “period effect” for
each variable with a 2-sample t test (or Mann-Whitney U
test for nonparametric variables) to compare the differ-
ences between the treatment periods in the latter 2 groups.
We tested for a “treatment-period interaction” with a 2-sam-
ple t test that compared the average of response to treat-
ment in each group. If a period effect or treatment-period
effect for each variable was found to be statistically non-
significant, then we calculated the differences between the
2 treatments with the Student t test (paired data) or the
Wilcoxon test (nonparametric data).
Results
Patients
There were 1,920 patients admitted during the study
period. We screened 32 patients and enrolled 12 men and
10 women (Table 1). Reasons for exclusion were: unstable
disease (4 patients), tracheotomy (1 patient), NIV (2 pa-
tients), and refusal (3 patients). All the patients completed
both airway clearance sessions. All the patients were clin-
ically stable, and had moderate hypoxemia, mild hyper-
capnia, obstructive pattern, and reduced respiratory mus-
cle function, but were able to cough spontaneously.
Response to Treatment
Table 2 shows the mean differences between IPV and
standard CPT in collected sputum and change in respira-
tory rate, heart rate (beats/min), and SpO2. IPV or CPT
were similarly safe in all the patients, as demonstrated by
stability or mild improvement in physiological response
during their application. In detail:
• SpO2 showed no significant variation with IPV or CPT
from T0 to T3: from 92  2% to 93  2% (P  .051)
with IPV, and from 93 2% to 93 3% (P .56) with
CPT. There was no significant difference between the
treatments (P  .34).
• With both IPV and CPT, heart rate significantly de-
creased from T0 to T3: from 86  11 beats/min to
82  11 beats/min with IPV (P  .002), and from
87 10 beats/min to 83 11 beats/min (P .038) with
CPT. There was no significant difference between the
treatments (P  .82).
• Respiratory rate significantly decreased with IPV, from
21  4 breaths/min at T0 to 19  4 breaths/min at T3
(P  .02), whereas it did not significantly change with
CPT (21  4 breaths/min at T0 versus 21  5 breaths/
min at T3, P  .58). There was a significant difference
between the treatments (P  .047).
Adverse effects (dry throat, nausea, and/or fatigue) oc-
curred in 27% of the patients with both IPV and CPT, but
the adverse effects were not serious enough to require
discontinuation of treatment.
Table 1. Baseline Characteristics (n  22)
Male/female, no. 12/10
Age (y) 64.4 8.9
FEV1 (% predicted) 53  30
FVC (% predicted) 69 21
PImax (% predicted) 48  29
PEmax (% predicted) 50  22
pH 7.41 0.03
PaO2 (mm Hg) 66  10
PaCO2 (mm Hg) 47  10
 values are mean  SD.
FVC  forced vital capacity
PImax  maximum inspiratory pressure
PEmax  maximum expiratory pressure
Table 2. Mean Differences Between Intrapulmonary Percussive
Ventilation and Standard Chest Physical Therapy
Mean
Difference 95% CI P
Sputum
Volume (mL) 0.68 3.80 to 2.43 .65
Wet weight (g) 3.00 8.48 to 14.48 .58
Dry weight (g) 0.31 0.87 to 0.26 .26
 Respiratory rate (breaths/min) 1.6 3.2 to 0.02 .047
 Heart rate (beats/min) 0.4 3.6 to 2.9 .82
 SpO2 (%) 0.6 0.7 to 2.0 .35
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Collected Sputum
With IPV and CPT, 29% of patients produced 20 mL,
41% produced 20–40 mL, 16% produced 40–60 mL, and
only 14% produced 60 mL of sputum at T3. At T3 there
were no significant differences between the groups in spu-
tum volume, wet weight, or dry weight (see Table 2).
Dyspnea
Dyspnea did not worsen with either treatment. IPV sig-
nificantly improved dyspnea, from 35  29% at T0 to
23  20% at T3 (P  .004), but CPT did not (33  27%
vs 27 26%, P .09). However, there was no significant
difference between the groups (P  .35).
Sensation of Phlegm Encumbrance
Sensation of phlegm encumbrance significantly im-
proved from T0 to T3 in both groups: from 47  35% to
27  32% with IPV (P  .001), and from 48  1% to
37  35% with CPT (P  .03). There was no significant
difference between the groups (P  .48).
Discomfort
Post-treatment mean IPV-induced discomfort was low-
er: 23  17% with IPV, versus 40  27% with CPT
(P  .03), though there was high variability in these mea-
surements (Fig. 1).
Discussion
In stable adults with bronchiectasis, IPV and CPT had a
similar safety profile and physiological and efficacy re-
sponse, but IPV had less discomfort. Previous studies have
found IPV safe, well tolerated, and effective in various
hypersecretive diseases,9,10,13,16,21 but to our knowledge
this is the first study of IPV in patients with bronchiectasis.
Tsurata et al15 and Van Ginderdeuren et al22 found no
significant changes of heart rate after IPV in 2 different
trials with obese and CF patients. Our study confirms IPV’s
cardiovascular safety in patients with bronchiectasis. Sim-
ilar to the study by Van Ginderdeuren et al,22 we observed
no change in SpO2.
In 2 physiological studies with animals, Banzett et al23
and Bohn et al24 investigated the effects of IPV on respi-
ratory control. Their data suggest that the rhythmic vari-
ations of pressure in the airways produced by high-fre-
quency percussions can induce a bradypnea reflex that
originates from mechanoreceptors and from rhythmic vi-
brations of the rib cage and intercostal muscles, and acts
on the respiratory centers. In patients with COPD exacer-
bation treated with IPV, Vargas et al13 observed respiratory-
rate reduction similar to what we found in our patients.
As in other studies,9,15 short-term IPV caused no major
adverse effects: we observed dry throat, nausea, and fa-
tigue, which are probably related to the pressurization of
air into the mouth and airways. We did not use humidifi-
cation during IPV, and it is reasonable to suppose that
humidification could reduce the incidence of these adverse
effects.
Van Ginderdeuren et al22 measured dyspnea with IPV
combined with autogenic drainage in 20 stable CF patients
and found no significant changes after 15 min of IPV. We
found significant dyspnea improvement after IPV, and we
speculate that this could be from a decrease in airways
resistance following expectoration. That we found reduced
perception of phlegm encumbrance with both IPV and
CPT supports that hypothesis.
We found less discomfort with IPV than with CPT. This
effect was similar to the one reported by Marks et al21 in
CF patients. Conversely, Varekojis et al25 found was no
significant difference in comfort between IPV, high-fre-
quency chest-wall compression, and CPT in pediatric CF
patients. Our finding might be explained by the discomfort
caused by frequent position changes, or by the fact that the
patient was in the lateral or prone position during CPT.
IPV was as effective as CPT in terms of sputum volume
and weight, which agrees with the findings of Natale et al9
in CF patients treated with IPV, aerosol therapy, and CPT.
Furthermore, in 24 CF patients Varekojis et al25 found wet
sputum weight significantly higher with IPV than with
either high-frequency chest-wall compression or CPT.
Limitations
Our test of IPV’s effectiveness was short-term, so we
cannot conclude that longer or repeated application of IPV
Fig. 1. Median, SD, and IQR of patient discomfort after 30 min of
intrapulmonary percussive ventilation versus standard chest phys-
ical therapy.
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would further improve outcomes. Also, we chose sputum
volume as a primary outcome, but we know that several
factors influence sputum volume, including rheological
characteristic of the sputum, and swallowing. We are also
aware that there is some difficulty in finding proper out-
come measures in studies of bronchial hygiene techniques.
Conclusions
Short-term IPV and CPT are similarly safe and effective
in patients with bronchiectasis and productive cough, and
IPV was associated with less discomfort. We recommend
studies on IPV’s cost-effectiveness before general clinical
application of IPV. However, as a practical clinical impli-
cation, our study suggests that, in a hospital setting, IPV is
safe in patients with bronchiectasis, and may be especially
useful with patients intolerant of CPT because they are
unable to maintain lateral or prone position or develop
bronchospasm or discomfort during manually assisted ma-
neuvers.4
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